Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:alvocidib
go back to main search page
Accession:CHEBI:47344 term browser browse the term
Definition:A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.
Synonyms:related_synonym: (-)-cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one;   2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-chromen-4-one;   Flavopiridol;   Formula=C21H20ClNO5;   HMR-1274;   InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1;   InChIKey=BIIVYFLTOXDAOV-YVEFUNNKSA-N;   L 86-8275;   L 868275;   L86-8275;   SMILES=C=12OC(=CC(C1C(=CC(=C2[C@@H]3[C@@H](CN(CC3)C)O)O)O)=O)C4=C(C=CC=C4)Cl;   alvocidibum
 xref: CAS:146426-40-6;   DrugBank:DB03496;   KEGG:D09868;   LINCS:LSM-1011
 xref_mesh: MESH:C077990
 xref: PDBeChem:CPB;   PMID:10441105;   PMID:1279187;   PMID:18209094;   PMID:21541623;   PMID:23959599;   PMID:25118834;   PMID:25216351;   PMID:25351763;   PMID:25623777;   PMID:25860066;   PMID:25989942;   PMID:26022709;   PMID:26521988;   PMID:26599132;   PMID:8002990;   PMID:9269999;   PMID:9815683;   Patent:EP241003;   Patent:US4900727;   Wikipedia:Alvocidib
 cyclic_relationship: is_conjugate_base_of CHEBI:90997


show annotations for term's descendants           Sort by:
 
alvocidib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein CTD PMID:15039284 NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 increases localization ISO alvocidib results in increased localization of AIFM1 protein CTD PMID:12734434 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form CTD PMID:15039284 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO [Imatinib Mesylate co-treated with alvocidib] results in decreased expression of BAD protein CTD PMID:12231544 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
JBrowse link
G Bag1 BAG cochaperone 1 decreases expression ISO alvocidib results in decreased expression of BAG1 mRNA; alvocidib results in decreased expression of BAG1 protein; alvocidib results in decreased expression of BAG1 protein alternative form CTD PMID:10887097 PMID:15972445 NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects localization
increases cleavage
increases expression
multiple interactions
ISO alvocidib affects the localization of BAX protein
alvocidib results in increased cleavage of BAX protein
alvocidib results in increased expression of BAX protein
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of BAX protein; [alvocidib co-treated with gemcitabine] results in increased expression of BAX protein; [alvocidib co-treated with TNFSF10 protein] results in increased localization of BAX protein; Epothilones promotes the reaction [alvocidib affects the localization of BAX protein]
CTD PMID:12517783 PMID:12589031 PMID:12734434 PMID:15634644 PMID:15770523 More... NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
decreases response to substance
multiple interactions
increases expression
ISO alvocidib results in decreased expression of BCL2 mRNA; alvocidib results in decreased expression of BCL2 protein
BCL2 protein mutant form results in decreased susceptibility to alvocidib; BCL2 protein results in decreased susceptibility to alvocidib
[alvocidib co-treated with gemcitabine] results in decreased expression of BCL2 protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein]; BCL2 protein results in decreased susceptibility to [alvocidib co-treated with Epothilones]
alvocidib results in increased expression of BCL2
CTD PMID:10887097 PMID:10995888 PMID:12170773 PMID:12517783 PMID:12589031 More... NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of BCL2L1 protein; Epothilones promotes the reaction [alvocidib results in decreased expression of BCL2L1 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of BCL2L1 protein]
alvocidib results in decreased expression of BCL2L1; alvocidib results in decreased expression of BCL2L1 mRNA; alvocidib results in decreased expression of BCL2L1 protein
CTD PMID:12517783 PMID:15039284 PMID:15634644 PMID:16820931 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions
increases cleavage
ISO [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of BID protein; [alvocidib co-treated with TNFSF10 protein] results in decreased expression of BID protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of BID protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; Boc-D-FMK inhibits the reaction [alvocidib results in increased cleavage of BID protein] CTD PMID:11464216 PMID:12170773 PMID:12231544 PMID:15634644 PMID:16951203 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
multiple interactions
ISO alvocidib results in decreased expression of BIRC3 mRNA; alvocidib results in decreased expression of BIRC3 protein
Epothilones promotes the reaction [alvocidib results in decreased expression of BIRC3 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of BIRC3 protein]
CTD PMID:12517783 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression
ISO [alvocidib co-treated with 7-hydroxystaurosporine] results in decreased expression of BIRC5 protein; [alvocidib co-treated with PBOX-6] results in decreased expression of BIRC5 protein; alvocidib inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of BIRC5 protein]; alvocidib results in decreased phosphorylation of and results in decreased expression of BIRC5 protein
alvocidib results in decreased expression of BIRC5; alvocidib results in decreased expression of BIRC5 mRNA; alvocidib results in decreased expression of BIRC5 protein
CTD PMID:12517783 PMID:12517802 PMID:16012789 PMID:16820931 PMID:20206141 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Btg2 BTG anti-proliferation factor 2 increases expression ISO alvocidib results in increased expression of BTG2 mRNA CTD PMID:21382384 NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
JBrowse link
G Casp3 caspase 3 affects cleavage
multiple interactions
increases cleavage
increases activity
ISO
EXP
alvocidib affects the cleavage of CASP3 protein
alvocidib inhibits the reaction [Colchicine results in increased activity of CASP3 protein]
alvocidib results in increased cleavage of CASP3 protein
alvocidib results in increased activity of CASP3 protein
[alvocidib co-treated with 7-hydroxystaurosporine] results in increased activity of CASP3 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP3 protein; [alvocidib co-treated with gemcitabine] results in increased cleavage of CASP3 protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of CASP3 protein; [irinotecan co-treated with alvocidib] results in increased activity of CASP3 protein; alvocidib affects the cleavage of and results in increased activity of CASP3 protein; alvocidib promotes the reaction [Paclitaxel results in increased activity of CASP3 protein]; alvocidib promotes the reaction [romidepsin results in increased activity of CASP3 protein]; alvocidib results in increased cleavage of and results in increased activity of CASP3 protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; Boc-D-FMK inhibits the reaction [alvocidib results in increased cleavage of and results in increased activity of CASP3 protein]
CTD PMID:9808574 PMID:10430095 PMID:10896673 PMID:11482875 PMID:11751522 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
ISO [alvocidib co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP8 protein; [alvocidib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of CASP8 protein
alvocidib results in increased cleavage of CASP8 protein
CTD PMID:10896673 PMID:12231544 PMID:12589031 PMID:15634644 PMID:16012789 More... NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 affects cleavage
increases activity
multiple interactions
ISO alvocidib affects the cleavage of CASP9 protein
alvocidib results in increased activity of CASP9 protein
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP9 protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein]
CTD PMID:10896673 PMID:12170773 PMID:15634644 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cbr3 carbonyl reductase 3 decreases expression ISO alvocidib results in decreased expression of CBR3 mRNA CTD PMID:21382384 NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
JBrowse link
G Ccna2 cyclin A2 multiple interactions ISO alvocidib results in decreased expression of and results in decreased activity of CCNA2 protein CTD PMID:16731754 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
JBrowse link
G Ccnb1 cyclin B1 multiple interactions
decreases expression
ISO [alvocidib co-treated with PBOX-6] results in decreased expression of CCNB1 protein; alvocidib inhibits the reaction [Paclitaxel results in increased expression of CCNB1 protein]; alvocidib results in decreased expression of and results in decreased activity of CCNB1 protein
alvocidib results in decreased expression of CCNB1 protein
CTD PMID:10430095 PMID:12517783 PMID:15014036 PMID:16731754 PMID:20206141 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
decreases activity
ISO [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of CCND1 protein
alvocidib results in decreased expression of CCND1 protein
alvocidib results in decreased activity of CCND1 protein
CTD PMID:9802881 PMID:9829756 PMID:10441105 PMID:12517783 PMID:12589031 More... NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccne1 cyclin E1 decreases expression ISO alvocidib results in decreased expression of CCNE1 protein CTD PMID:15014036 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
decreases expression
decreases activity
ISO [alvocidib co-treated with PBOX-6] results in decreased activity of CDK1 protein
alvocidib results in decreased expression of CDK1 protein modified form
alvocidib results in decreased activity of CDK1 protein
CTD PMID:9427698 PMID:9802881 PMID:12517783 PMID:16905211 PMID:20206141 More... NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression
decreases activity
multiple interactions
ISO alvocidib results in decreased expression of CDK2 protein modified form
alvocidib results in decreased activity of CDK2 protein
alvocidib binds to and results in decreased activity of CDK2 protein; alvocidib inhibits the reaction [Paclitaxel results in increased activity of CDK2 protein]
CTD PMID:9802881 PMID:10430095 PMID:12517783 PMID:16905211 PMID:24102143 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases activity
multiple interactions
decreases expression
ISO alvocidib results in decreased activity of CDK4 protein
alvocidib binds to and results in decreased activity of CDK4 protein
alvocidib results in decreased expression of CDK4 protein
CTD PMID:12517783 PMID:12734434 PMID:24102143 NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
JBrowse link
G Cdk5 cyclin-dependent kinase 5 multiple interactions EXP alvocidib inhibits the reaction [Colchicine results in increased expression of CDK5 protein] CTD PMID:12941380 NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
JBrowse link
G Cdk9 cyclin-dependent kinase 9 multiple interactions ISO alvocidib binds to and results in decreased activity of CDK9 protein CTD PMID:24102143 NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
decreases expression
increases cleavage
increases expression
affects expression
ISO [alvocidib co-treated with gemcitabine] results in increased expression of CDKN1A protein; alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A promoter]; alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]; Phorbol 12,13-Dibutyrate inhibits the reaction [alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]]
alvocidib results in decreased expression of CDKN1A protein
alvocidib results in increased cleavage of CDKN1A protein
alvocidib results in increased expression of CDKN1A protein
alvocidib affects the expression of CDKN1A protein
CTD PMID:10537362 PMID:12734434 PMID:15014036 PMID:15180955 PMID:15770523 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases cleavage
increases expression
ISO alvocidib results in increased cleavage of CDKN1B protein
[alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein; alvocidib results in increased expression of CDKN1B protein
CTD PMID:10537362 PMID:12589031 PMID:15180955 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression
multiple interactions
decreases expression
ISO alvocidib affects the expression of CFLAR mRNA
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alvocidib results in decreased expression of CFLAR protein]
alvocidib results in decreased expression of CFLAR; alvocidib results in decreased expression of CFLAR protein
CTD PMID:16820931 PMID:16951203 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein CTD PMID:15039284 NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
JBrowse link
G Cycs cytochrome c, somatic affects localization
multiple interactions
ISO alvocidib affects the localization of CYCS protein
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of CYCS protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein]
CTD PMID:12170773 PMID:12517783 PMID:15634644 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein affects localization
multiple interactions
ISO alvocidib affects the localization of DIABLO protein
[alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of DIABLO protein; [Imatinib Mesylate co-treated with alvocidib] results in increased secretion of DIABLO protein
CTD PMID:12231544 PMID:12517783 PMID:15039284 PMID:15634644 NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
JBrowse link
G E2f1 E2F transcription factor 1 increases expression
increases response to substance
decreases expression
ISO alvocidib results in increased expression of E2F1 protein
E2F1 results in increased susceptibility to alvocidib
alvocidib results in decreased expression of E2F1 mRNA
CTD PMID:12533675 PMID:21239698 NCBI chr 3:143,064,535...143,075,362 JBrowse link
G H2ax H2A.X variant histone affects expression ISO alvocidib affects the expression of H2AX protein CTD PMID:15078984 NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G Hmga1 high mobility group AT-hook 1 decreases expression ISO alvocidib results in decreased expression of HMGA1 mRNA CTD PMID:21239698 NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
JBrowse link
G Htra2 HtrA serine peptidase 2 affects localization ISO alvocidib affects the localization of HTRA2 protein CTD PMID:12517783 NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
JBrowse link
G Ifit1 interferon-induced protein with tetratricopeptide repeats 1 multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]] CTD PMID:23589332 NCBI chr 1:232,152,038...232,154,103
Ensembl chr 1:232,127,170...232,154,435
JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein results in increased expression of ISG15 mRNA] CTD PMID:23589332 NCBI chr 5:103,020,969...103,021,523
Ensembl chr 5:103,020,969...103,021,523
JBrowse link
G Isg15 ISG15 ubiquitin-like modifier multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein results in increased expression of ISG15 mRNA] CTD PMID:23589332 NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Imatinib Mesylate co-treated with alvocidib] results in increased activity of JUN protein CTD PMID:12231544 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase decreases expression
decreases phosphorylation
ISO alvocidib results in decreased expression of KIT mRNA; alvocidib results in decreased expression of KIT promoter
alvocidib results in decreased phosphorylation of KIT protein
CTD PMID:16740725 NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein CTD PMID:15039284 NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions ISO alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein] CTD PMID:15039284 NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; alvocidib results in decreased activity of and results in decreased phosphorylation of MAPK1 protein CTD PMID:15014036 PMID:15039284 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased phosphorylation of and results in increased activity of MAPK14 protein CTD PMID:15634644 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; alvocidib results in decreased activity of and results in decreased phosphorylation of MAPK3 protein CTD PMID:15014036 PMID:15039284 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased phosphorylation of and results in increased activity of MAPK8 protein; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein] CTD PMID:15039284 PMID:15634644 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member affects expression
decreases response to substance
decreases expression
multiple interactions
ISO alvocidib affects the expression of MCL1 mRNA; alvocidib affects the expression of MCL1 protein
MCL1 results in decreased susceptibility to alvocidib
alvocidib results in decreased expression of MCL1 mRNA; alvocidib results in decreased expression of MCL1 protein
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of MCL1 protein; [Imatinib Mesylate co-treated with alvocidib] results in decreased expression of MCL1 protein; Epothilones promotes the reaction [alvocidib results in decreased expression of MCL1 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of MCL1 protein]
CTD PMID:10887097 PMID:12231544 PMID:12429644 PMID:12517783 PMID:12533675 More... NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Mdm2 MDM2 proto-oncogene decreases expression ISO alvocidib results in decreased expression of MDM2 mRNA; alvocidib results in decreased expression of MDM2 protein CTD PMID:12589031 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
JBrowse link
G Mx1 MX dynamin like GTPase 1 multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]] CTD PMID:23589332 NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507
JBrowse link
G Nelfa negative elongation factor complex member A multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]] CTD PMID:23589332 NCBI chr14:76,808,920...76,832,998
Ensembl chr14:76,808,870...76,832,994
JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression
multiple interactions
ISO alvocidib results in increased expression of NFKBIA protein modified form
alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form]
CTD PMID:15039284 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO alvocidib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] CTD PMID:25257666 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO [alvocidib co-treated with 7-hydroxystaurosporine] results in increased cleavage of PARP1 protein; [alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of PARP1 protein; [alvocidib co-treated with gemcitabine] results in increased cleavage of PARP1 protein; alvocidib promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein] CTD PMID:10430095 PMID:12170773 PMID:12517783 PMID:15039284 PMID:15634644 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pawr pro-apoptotic WT1 regulator multiple interactions EXP alvocidib inhibits the reaction [Colchicine results in increased expression of PAWR protein] CTD PMID:12941380 NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028
JBrowse link
G Pcna proliferating cell nuclear antigen decreases activity ISO alvocidib results in decreased activity of PCNA protein CTD PMID:10441105 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Perp p53 apoptosis effector related to PMP22 increases expression ISO alvocidib results in increased expression of PERP mRNA CTD PMID:21382384 NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511
JBrowse link
G Polr2a RNA polymerase II subunit A decreases expression
decreases phosphorylation
multiple interactions
ISO alvocidib results in decreased expression of POLR2A mRNA
alvocidib results in decreased phosphorylation of POLR2A protein
Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein]
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]
CTD PMID:15039284 PMID:21239698 PMID:23589332 PMID:24102143 NCBI chr10:54,452,438...54,478,486
Ensembl chr10:54,452,441...54,478,455
JBrowse link
G Pygb glycogen phosphorylase B affects binding ISO PYGB protein binds to alvocidib CTD PMID:11368340 NCBI chr 3:139,611,724...139,658,521
Ensembl chr 3:139,611,749...139,663,553
JBrowse link
G Pygl glycogen phosphorylase L affects binding ISO PYGL protein binds to alvocidib CTD PMID:11368340 NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases activity
decreases response to substance
multiple interactions
decreases phosphorylation
decreases expression
ISO alvocidib results in decreased activity of RB1 protein modified form
RB1 results in decreased susceptibility to alvocidib
[docetaxel co-treated with alvocidib] results in decreased phosphorylation of and results in decreased expression of RB1 protein
alvocidib results in decreased phosphorylation of RB1 protein
alvocidib results in decreased expression of RB1 protein; alvocidib results in decreased expression of RB1 protein modified form
CTD PMID:9829756 PMID:10441105 PMID:15180955 PMID:15297405 PMID:16905211 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
JBrowse link
G Rbl1 RB transcriptional corepressor like 1 decreases expression ISO alvocidib results in decreased expression of RBL1 protein CTD PMID:9829756 NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
decreases expression
ISO [alvocidib co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased activity of STAT3 protein
alvocidib results in decreased expression of STAT3 mRNA
CTD PMID:15039284 PMID:21239698 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Supt5h SPT5 homolog, DSIF elongation factor subunit multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]] CTD PMID:23589332 NCBI chr 1:83,586,713...83,616,971
Ensembl chr 1:83,586,718...83,616,892
JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases activity ISO alvocidib analog results in decreased activity of TGFB1 protein CTD PMID:31652400 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO alvocidib inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] CTD PMID:21204955 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b increases expression ISO alvocidib results in increased expression of TNFRSF10A CTD PMID:16820931 NCBI chr15:44,839,818...44,867,582 JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions
increases response to substance
increases expression
ISO [alvocidib co-treated with TNFSF10 protein] results in decreased expression of BID protein; [alvocidib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [alvocidib co-treated with TNFSF10 protein] results in increased localization of BAX protein
alvocidib results in increased susceptibility to TNFSF10
alvocidib results in increased expression of TNFSF10
CTD PMID:16820931 PMID:16951203 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
JBrowse link
G Tp53 tumor protein p53 decreases expression
multiple interactions
increases expression
ISO alvocidib results in decreased expression of TP53 protein
[docetaxel co-treated with alvocidib] results in increased expression of TP53 protein
[alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein; alvocidib results in increased expression of TP53 protein
CTD PMID:9808574 PMID:10537362 PMID:12589031 PMID:15180955 PMID:15297405 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression ISO alvocidib results in decreased expression of VEGFA mRNA CTD PMID:21239698 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression
multiple interactions
ISO alvocidib results in decreased expression of XIAP mRNA; alvocidib results in decreased expression of XIAP protein
[irinotecan co-treated with alvocidib] results in increased cleavage of XIAP protein; Epothilones promotes the reaction [alvocidib results in decreased expression of XIAP mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of XIAP protein]
CTD PMID:10887097 PMID:11751522 PMID:12517783 PMID:15385934 PMID:15972445 More... NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19821
    role 19769
      biological role 19769
        biochemical role 19389
          apoptosis inducer 13236
            alvocidib 70
Path 2
Term Annotations click to browse term
  CHEBI ontology 19821
    subatomic particle 19819
      composite particle 19819
        hadron 19819
          baryon 19819
            nucleon 19819
              atomic nucleus 19819
                atom 19819
                  main group element atom 19716
                    p-block element atom 19716
                      carbon group element atom 19640
                        carbon atom 19630
                          organic molecular entity 19630
                            organic molecule 19569
                              organic cyclic compound 19360
                                organic heterocyclic compound 18591
                                  oxacycle 17587
                                    benzopyran 10402
                                      1-benzopyran 10129
                                        flavonoid 6513
                                          flavones 4203
                                            hydroxyflavone 4191
                                              dihydroxyflavone 485
                                                alvocidib 70
paths to the root